These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23415781)

  • 1. Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.
    Dumas EK; Nguyen ML; Cox PM; Rodgers H; Peterson JL; James JA; Farris AD
    Vaccine; 2013 Apr; 31(14):1856-63. PubMed ID: 23415781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
    Nguyen ML; Crowe SR; Kurella S; Teryzan S; Cao B; Ballard JD; James JA; Farris AD
    Infect Immun; 2009 Jan; 77(1):162-9. PubMed ID: 18981257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes.
    Nguyen ML; Terzyan S; Ballard JD; James JA; Farris AD
    Infect Immun; 2009 Nov; 77(11):4714-23. PubMed ID: 19720758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.
    Abboud N; Casadevall A
    Clin Vaccine Immunol; 2008 Jul; 15(7):1115-23. PubMed ID: 18480236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
    Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
    Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
    Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
    Welkos S; Little S; Friedlander A; Fritz D; Fellows P
    Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.
    Crowe SR; Garman L; Engler RJ; Farris AD; Ballard JD; Harley JB; James JA
    Vaccine; 2011 May; 29(20):3670-8. PubMed ID: 21420416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.
    Staats HF; Alam SM; Scearce RM; Kirwan SM; Zhang JX; Gwinn WM; Haynes BF
    Infect Immun; 2007 Nov; 75(11):5443-52. PubMed ID: 17709410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
    Yan M; Roehrl MH; Basar E; Wang JY
    Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.
    Gorantala J; Grover S; Goel D; Rahi A; Jayadev Magani SK; Chandra S; Bhatnagar R
    Vaccine; 2011 Jun; 29(27):4521-33. PubMed ID: 21504775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen.
    Oscherwitz J; Yu F; Cease KB
    Infect Immun; 2009 Dec; 77(12):5509-18. PubMed ID: 19805525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
    Park YS; Lee JH; Hung CF; Wu TC; Kim TW
    Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
    Dumas EK; Garman L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Choudhari S; Picking WD; James JA; Farris AD
    Vaccine; 2017 Jun; 35(26):3416-3422. PubMed ID: 28504191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes.
    Dumas EK; Demiraslan H; Ingram RJ; Sparks RM; Muns E; Zamora A; Larabee J; Garman L; Ballard JD; Boons GJ; James JA; Kayabas U; Doganay M; Farris AD
    PLoS One; 2020; 15(4):e0230782. PubMed ID: 32294093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the human immune response to the UK anthrax vaccine.
    Baillie L; Townend T; Walker N; Eriksson U; Williamson D
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):267-70. PubMed ID: 15364114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
    Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A
    Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of a novel multiepitope chimeric vaccine against anthrax.
    Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
    Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
    Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
    Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.